AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270 USD | +0.22% |
|
+0.39% | -6.26% |
| Apr. 26 | Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe | MT |
| Apr. 26 | Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza | DJ |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 120 M€ | +12.61% | - | |
| 3.71% | 18 M€ | +3.79% | - | |
| 3.24% | 1 M€ | -5.79% | - | |
| 2.61% | 1 M€ | +2.21% | - | |
| 1.75% | 4,592 M€ | +11.18% | ||
| 1.73% | 9 M€ | -4.31% | - | |
| 1.67% | 9 M€ | -.--% | - | |
| 1.65% | 8 M€ | +2.44% | ||
| 1.55% | 846 M€ | +2.60% | ||
| 1.37% | 2 M€ | +20.44% | - | |
| 1.31% | 5 M€ | -72.95% | - | |
| 1.29% | 3 M€ | 0.00% | - | |
| 1.19% | 22 M€ | 0.00% | - | |
| 1.04% | 3,859 M€ | +18.82% | - | |
| 1.04% | 469 M€ | -2.05% | - | |
| 1.04% | 1,182 M€ | +1.06% | ||
| 0.88% | 2 M€ | +6.77% | ||
| 0.77% | 282 M€ | +3.59% | - | |
| 0.75% | 7 M€ | +0.11% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
270
USD
Average target price
300.3
USD
Spread / Average Target
+11.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.26% | 145B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -11.77% | 144B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.
